| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6268343 | NOVO | Derivatives of GLP-1 analogs |
Aug, 2022
(1 year, 1 month ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9486588 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(1 year, 8 months ago) | |
| US8672898 | NOVO | Automatic injection device with reset feature |
Jan, 2022
(1 year, 8 months ago) | |
| US8846618 | NOVO | Stable formulation of modified GLP-1 |
Jun, 2022
(1 year, 3 months ago) | |
|
US6899699 (Pediatric) | NOVO | Automatic injection device with reset feature |
Jul, 2022
(1 year, 2 months ago) | |
|
US9486588 (Pediatric) | NOVO | Automatic injection device with reset feature |
Jul, 2022
(1 year, 2 months ago) | |
|
US8672898 (Pediatric) | NOVO | Automatic injection device with reset feature |
Jul, 2022
(1 year, 2 months ago) | |
|
US8846618 (Pediatric) | NOVO | Stable formulation of modified GLP-1 |
Dec, 2022
(9 months ago) | |
|
US6268343 (Pediatric) | NOVO | Derivatives of GLP-1 analogs |
Feb, 2023
(7 months ago) | |
| US8579869 | NOVO | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(3 months ago) | |
|
US8579869 (Pediatric) | NOVO | Needle mounting system and a method for mounting a needle assembly |
Dec, 2023
(2 months from now) | |
| US7762994 | NOVO | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(7 months from now) | |
|
US7762994 (Pediatric) | NOVO | Needle mounting system and a method for mounting a needle assembly |
Nov, 2024
(1 year, 1 month from now) | |
| US8114833 | NOVO | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(1 year, 10 months from now) | |
| US8684969 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(2 years from now) | |
| US11446443 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(2 years from now) | |
| US10357616 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(2 years from now) | |
| US10376652 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(2 years from now) | |
| US11311679 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(2 years from now) | |
| US9616180 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(2 years from now) | |
| US9861757 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(2 years from now) | |
| US9108002 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(2 years from now) | |
|
US8114833 (Pediatric) | NOVO | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Feb, 2026
(2 years from now) | |
|
US8684969 (Pediatric) | NOVO | Injection device with torsion spring and rotatable display |
Apr, 2026
(2 years from now) | |
| US9775953 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(2 years from now) | |
| US10220155 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(2 years from now) | |
| US11097063 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(2 years from now) | |
| US8920383 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(2 years from now) | |
|
US9861757 (Pediatric) | NOVO | Injection device with an end of dose feedback mechanism |
Jul, 2026
(2 years from now) | |
|
US9616180 (Pediatric) | NOVO | Automatic injection device with a top release mechanism |
Jul, 2026
(2 years from now) | |
|
US9108002 (Pediatric) | NOVO | Automatic injection device with a top release mechanism |
Jul, 2026
(2 years from now) | |
| USRE46363 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(2 years from now) | |
|
US10220155 (Pediatric) | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jan, 2027
(3 years from now) | |
|
US8920383 (Pediatric) | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jan, 2027
(3 years from now) | |
|
US9775953 (Pediatric) | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jan, 2027
(3 years from now) | |
|
USRE46363 (Pediatric) | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2027
(3 years from now) | |
| US9687611 | NOVO | Injection device with torsion spring and rotatable display |
Feb, 2027
(3 years from now) | |
|
US9687611 (Pediatric) | NOVO | Injection device with torsion spring and rotatable display |
Aug, 2027
(3 years from now) | |
| US9457154 | NOVO | Injection device with an end of dose feedback mechanism |
Sep, 2027
(3 years from now) | |
|
US9457154 (Pediatric) | NOVO | Injection device with an end of dose feedback mechanism |
Mar, 2028
(4 years from now) | |
| US9132239 | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2032
(8 years from now) | |
|
US9132239 (Pediatric) | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2032
(8 years from now) | |
| US9968659 | NOVO | Liraglutide in cardiovascular conditions |
Jan, 2037
(13 years from now) | |
|
US9968659 (Pediatric) | NOVO | Liraglutide in cardiovascular conditions |
Jul, 2037
(13 years from now) | |
Saxenda is owned by Novo.
Saxenda contains Liraglutide Recombinant.
Saxenda has a total of 44 drug patents out of which 10 drug patents have expired.
Expired drug patents of Saxenda are:
- US9486588
- US8672898
- US8846618
- US6899699*PED
- US9486588*PED
- US8672898*PED
- US8846618*PED
- US6268343*PED
- US8579869
- US6268343
Saxenda was authorised for market use on 23 December, 2014.
Saxenda is available in solution;subcutaneous dosage forms.
Saxenda can be used as cardiovascular outcomes trial of liraglutide 1.8 mg in patients with type 2 diabetes and cardiovascular disease, method for chronic weight management by treating obesity.
The generics of Saxenda are possible to be released after 09 July, 2037.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Dec 4, 2023 |
Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient
Market Authorisation Date: 23 December, 2014
Treatment: Cardiovascular outcomes trial of liraglutide 1.8 mg in patients with type 2 diabetes and cardiovascular disease; Method for chronic weight management by treating obesity
Dosage: SOLUTION;SUBCUTANEOUS
SAXENDA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic